As of 2024, cellular therapies are newly approved for the treatment of advanced SS.8 T-cells with engineered T-cell receptors (TCRs) against highly-expressed cancer testis antigens, such as melanoma-associated antigen A4 (MAGE-A4)9,10 and New York esophageal squamous cell carcinoma 1 (NY-ESO-1),11,12 have shown safety and efficacy. The gene discussed is MAGEA4; the disease is synovial sarcoma.